Glenmark’s FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet
Mumbai-based Glenmark Pharmaceuticals have launched a new antiviral drug – Favipiravir with brand name FabiFlu – for the treatment of mild to moderate Covid-19 patients. The firm has become the first Indian company to commercially launch the antiviral drug.
Coronavirus replication
RdRp is the main enzyme of transcription-replication complex
Favipiravir mechanism of action and its study
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Potential coronavirus drug approved for marketing
Favipiravir, an antiviral that has shown potential in treating the novel coronavirus, was approved for marketing, the Taizhou government of Zhejiang province announced Sunday.
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
Fujifilm Announces the Start of a Phase III Clinical Trial of Influenza Antiviral Drug Avigan (favipiravir) on COVID-19 in Japan and Commits to Increasing Production
